Ghent, Belgium – October 28, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award. Each year the award, administered by […]
Archive for the
‘2022’ Category
Ghent, Belgium – September 15, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it will present highlights from the preclinical profiling of CFTX-1554, Confo’s lead clinical candidate in neuropathic pain, during the International Association for the Study of Pain (IASP) 2022 World Congress on […]
Ghent, Belgium – June 28, 2022 – Confo Therapeutics announced today that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The award further validates and supports Confo’s leadership in the discovery of novel GPCR (G protein-coupled receptor) drug candidates using its proprietary universal ConfoBody® technology, specifically for the […]
— Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel inhibitor […]